XORTX Therapeutics Files January 2025 Report
Ticker: XRTX · Form: 6-K · Filed: Jan 29, 2025 · CIK: 1729214
Sentiment: neutral
Topics: regulatory-filing, 6-K
TL;DR
XORTX filed its Jan 2025 6-K, confirming 20-F annual reports. CEO Davidoff signed off.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on January 29, 2025, to report its activities for the month of January 2025. The filing indicates the company is a foreign private issuer and will file annual reports under Form 20-F. The report is signed by CEO Allen Davidoff.
Why It Matters
This filing provides an update on XORTX Therapeutics' regulatory status and reporting for the month, which is important for investors tracking the company's compliance and ongoing operations.
Risk Assessment
Risk Level: low — This is a routine administrative filing (Form 6-K) that does not contain new financial or operational material information.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- January 29, 2025 (date) — Filing Date
FAQ
What type of report is XORTX Therapeutics Inc. filing?
XORTX Therapeutics Inc. is filing a Form 6-K, which is a Report of Foreign Private Issuer.
What period does this Form 6-K cover?
This Form 6-K covers the month of January 2025.
Which form will XORTX Therapeutics Inc. use for its annual reports?
XORTX Therapeutics Inc. will file its annual reports under cover of Form 20-F.
Who signed the Form 6-K on behalf of XORTX Therapeutics Inc.?
The Form 6-K was signed by Allen Davidoff, Chief Executive Officer.
What is the filing date of this report?
The filing date of this report is January 29, 2025.
Filing Stats: 139 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2025-01-29 07:03:57
Filing Documents
- f6k_012925.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 5KB
- 0001171843-25-000494.txt ( ) — 11KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date: January 29, 2025 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 News release dated January 29, 2025